【美股异动 | Nektar Therapeutics(NKTR.US)大涨近30% 湿疹治疗药物临床研究取得超预期积极

智通财经
25 Jun
【美股异动 | Nektar Therapeutics(NKTR.US)大涨近30% 湿疹治疗药物临床研究取得超预期积极结果】智通财经APP获悉,周三,Nektar Therapeutics(NKTR.US)大涨近30%,报31.70美元。消息面上,Nektar此前公布,其用于治疗中重度特应性皮炎(也被称作湿疹)的药物 Rezpegaldesleukin在REZOLVE-AD 2b 期临床研究中取得超预期的积极结果,达到主要和次要终点,验证了公司以新型调节性T细胞治疗炎症性皮肤疾病的全新思路。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10